title: New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials.
abstract: Tyrosine kinases (TKs) is a family of tyrosine protein kinases with important functions in the regulation of a broad variety of physiological cell processes. Overactivity of TK disturbs cellular homeostasis and has been linked to the development of certain diseases, including various fibrotic diseases. In regard to liver fibrosis, several TKs, such as vascular endothelial growth factor receptor, platelet-derived growth factor receptor, fibroblast growth factor receptor, and epidermal growth factor receptor kinases, have been identified as central mediators in collagen production and potential targets for anti-liver fibrosis therapies. Given the essential role of TKs during liver fibrogenesis, multitargeted inhibitors of aberrant TK activity, including sorafenib, erlotinib, imatinib, sunitinib, nilotinib, brivanib and vatalanib, have been shown to have potential for treating liver fibrosis. Beneficial effects are observed by researchers of this field using these multitargeted TK inhibitors in preclinical animal models and in patients with liver fibrosis. The present review will briefly summarize the anti-liver fibrosis effects of multitargeted TK inhibitors and molecular mechanisms.
authors.affiliation: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University Xi'an, China.
authors.forename: Kai
authors.initials: K
authors.lastname: Qu
authors.affiliation: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong UniversityXi'an, China; Department of General Surgery, Shaanxi Cancer HospitalXi'an, China.
authors.forename: Zichao
authors.initials: Z
authors.lastname: Huang
authors.affiliation: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University Xi'an, China.
authors.forename: Ting
authors.initials: T
authors.lastname: Lin
authors.affiliation: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University Xi'an, China.
authors.forename: Sinan
authors.initials: S
authors.lastname: Liu
authors.affiliation: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong UniversityXi'an, China; Department of Hepatobiliary Surgery, Shaanxi Provincial People's HospitalXi'an, China.
authors.forename: Hulin
authors.initials: H
authors.lastname: Chang
authors.affiliation: Department of Pain Treatment, Tangdu Hospital, Fourth Military Medical University Xi'an, China.
authors.forename: Zhaoyong
authors.initials: Z
authors.lastname: Yan
authors.affiliation: Department of Pain Treatment, Tangdu Hospital, Fourth Military Medical University Xi'an, China.
authors.forename: Hongxin
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University Xi'an, China.
authors.forename: Chang
authors.initials: C
authors.lastname: Liu
keywords: clinical trials; liver fibrosis; molecular mechanisms; preclinical study; tyrosine kinase inhibitors
references.citation: Hepatology. 2011 Aug;54(2):573-85
references.pmid: 21567441
references.citation: Toxicol Appl Pharmacol. 2014 Jan 15;274(2):328-38
references.pmid: 24321339
references.citation: Oncologist. 2007 Apr;12(4):426-37
references.pmid: 17470685
references.citation: Nat Rev Drug Discov. 2010 Dec;9(12):956-70
references.pmid: 21119733
references.citation: Int J Mol Med. 2006 May;17(5):899-904
references.pmid: 16596278
references.citation: J Neuroimmune Pharmacol. 2014 Mar;9(2):69-79
references.pmid: 23793451
references.citation: Semin Liver Dis. 2009 Feb;29(1):3-18
references.pmid: 19235656
references.citation: J Gastroenterol Hepatol. 2014 May;29(5):1073-82
references.pmid: 24325631
references.citation: Nat Rev Drug Discov. 2007 Sep;6(9):734-45
references.pmid: 17690708
references.citation: Clin Exp Pharmacol Physiol. 2014 Oct;41(10):788-97
references.pmid: 25115651
references.citation: J Hepatol. 2006 Jan;44(1):167-75
references.pmid: 16168515
references.citation: Gut. 2003 Sep;52(9):1347-54
references.pmid: 12912869
references.citation: FASEB J. 2005 Jan;19(1):1-11
references.pmid: 15629889
references.citation: Expert Opin Pharmacother. 2003 Jun;4(6):963-71
references.pmid: 12783592
references.citation: Hepatology. 2009 Apr;49(4):1245-56
references.pmid: 19137587
references.citation: Med Oncol. 2010 Sep;27(3):768-73
references.pmid: 19662540
references.citation: Cancer Res. 2007 Oct 1;67(19):9443-54
references.pmid: 17909054
references.citation: Hepatology. 2004 May;39(5):1185-95
references.pmid: 15122744
references.citation: J Pharmacol Exp Ther. 2005 Dec;315(3):971-9
references.pmid: 16002463
references.citation: Eur J Pharmacol. 2013 Apr 5;705(1-3):86-95
references.pmid: 23454556
references.citation: Korean J Hepatol. 2007 Sep;13(3):309-19
references.pmid: 17898548
references.citation: J Pharmacol Exp Ther. 2007 Jun;321(3):856-65
references.pmid: 17369283
references.citation: J Gastrointest Surg. 2012 Feb;16(2):361-9
references.pmid: 22068968
references.citation: Exp Ther Med. 2010 Sep;1(5):863-866
references.pmid: 22993610
references.citation: PLoS One. 2014 Apr 07;9(4):e92273
references.pmid: 24710173
references.citation: Cancer Chemother Pharmacol. 2006 May;57(5):685-92
references.pmid: 16133532
references.citation: J Vasc Interv Radiol. 2012 Jul;23 (7):949-52
references.pmid: 22720895
references.citation: Lab Invest. 2009 Oct;89(10):1152-60
references.pmid: 19668241
references.citation: Biochim Biophys Acta. 2013 Aug;1833(8):1992-2003
references.pmid: 23499874
references.citation: Br J Clin Pharmacol. 2014 Jun;77(6):929-38
references.pmid: 23981115
references.citation: Gastroenterology. 2008 May;134(6):1655-69
references.pmid: 18471545
references.citation: Biochim Biophys Acta. 2013 Jul;1832(7):897-904
references.pmid: 22728287
references.citation: Aliment Pharmacol Ther. 2012 Jan;35(1):83-91
references.pmid: 22032637
references.citation: Cancer Res. 2010 May 15;70(10):3857-60
references.pmid: 20406984
references.citation: Fundam Clin Pharmacol. 2011 Apr;25(2):248-57
references.pmid: 20408881
references.citation: Toxicol Appl Pharmacol. 2011 Apr 15;252(2):165-75
references.pmid: 21316382
references.citation: Hepatology. 2007 Dec;46(6):1919-26
references.pmid: 17935226
references.citation: Drug Saf. 2013 Jul;36(7):491-503
references.pmid: 23620168
references.citation: Eur J Pharmacol. 2011 Nov 30;670(2-3):593-600
references.pmid: 21925495
references.citation: Br J Pharmacol. 2009 May;157(2):258-70
references.pmid: 19338580
references.citation: J Exp Med. 2005 Mar 21;201(6):925-35
references.pmid: 15781583
references.citation: Clin Sci (Lond). 2015 Oct 1;129(8):699-710
references.pmid: 26201021
references.citation: Dig Dis Sci. 2013 Jan;58(1):257-64
references.pmid: 22918681
references.citation: J Hepatol. 2010 Nov;53(5):976-80
references.pmid: 20800926
references.citation: Curr Cancer Drug Targets. 2008 Feb;8(1):76-85
references.pmid: 18288945
references.citation: Clin Sci (Lond). 2013 Apr;124(7):457-66
references.pmid: 23043394
references.citation: BMC Gastroenterol. 2015 Nov 16;15:159
references.pmid: 26572488
references.citation: Hepatology. 2014 Apr;59(4):1577-90
references.pmid: 24677197
references.citation: PLoS One. 2014 Apr 22;9(4):e95462
references.pmid: 24755660
references.citation: Lab Invest. 2009 Feb;89(2):209-21
references.pmid: 19114984
references.citation: Clin Cancer Res. 2012 Apr 1;18(7):2099-107
references.pmid: 22307138
references.citation: J Clin Invest. 2004 Nov;114(9):1308-16
references.pmid: 15520863
references.citation: Gastroenterol Clin Biol. 2010 Sep;34(8-9):446-9
references.pmid: 20630674
references.citation: Curr Drug Targets. 2010 Sep;11(9):1169-80
references.pmid: 20450475
references.citation: Inflammopharmacology. 2011 Dec;19(6):307-16
references.pmid: 21947519
references.citation: Braz J Med Biol Res. 2015 May;48(5):408-14
references.pmid: 25714891
references.citation: Internist (Berl). 2011 May;52(5):595-600
references.pmid: 21503656
references.citation: Arthritis Rheum. 2009 Jan;60(1):219-24
references.pmid: 19116940
references.citation: Ann Oncol. 2005 Oct;16(10):1688-94
references.pmid: 16006586
references.citation: Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G907-13
references.pmid: 15618280
references.citation: Eur J Clin Invest. 2012 Dec;42(12):1309-16
references.pmid: 23078180
references.citation: PLoS One. 2011 Feb 14;6(2):e16978
references.pmid: 21340026
references.citation: J Hepatol. 2010 Jul;53(1):132-44
references.pmid: 20447716
references.citation: Clin Cancer Res. 2005 Aug 1;11(15):5472-80
references.pmid: 16061863
references.citation: Liver Int. 2014 Apr;34(4):521-34
references.pmid: 23998651
references.citation: Br J Cancer. 2005 May 23;92(10):1855-61
references.pmid: 15870716
references.citation: Am J Gastroenterol. 2009 Jan;104(1):257-8
references.pmid: 19098892
references.citation: Annu Rev Pathol. 2011;6:425-56
references.pmid: 21073339
references.citation: Am J Gastroenterol. 2008 Aug;103(8):2162-3
references.pmid: 18796127
references.citation: J Hepatol. 2011 Sep;55(3):612-25
references.pmid: 21251937
references.citation: Am J Hematol. 2006 Mar;81(3):189-92
references.pmid: 16493605